This article is more than 5 years old. Information may no longer be current.
FDA approves endovascular system for thoracic aortic aneurysm repair
Click Here to Manage Email Alerts
Medtronic announced that the FDA has approved its Talent Captivia Delivery System for endovascular repair of thoracic aortic aneurysms.
According to a press release, the new system features a tip capture mechanism for controlled deployment and precise placement of the implantable medical device. During thoracic endovascular repair, the system is inserted into the femoral artery and moved up through blood vessels to the aorta. To help ease insertion and navigation en route toward the aorta, the device features the hydrophilic coating of the Captivia Delivery System.
Once in place, physicians expand the stent graft within the aorta, which creates a new blood flow path that reduces pressure on the aneurysm, as well as the risk of rupture and its often fatal consequences. The device is going to target the estimated 60,000 people in the US currently with thoracic aortic aneurysms, according to the release from Medtronic.
“The Captivia approval will increase the number and complexity of aortic pathologies that can be treated,” Edward Y. Woo, MD, vice-chief and program director of vascular surgery and endovascular therapy for the University of Pennsylvania Hospital System, said in an interview with Cardiology Today. “It allows for more varied anatomy and more precise deployment of the device. I am excited about the approval and applying this technology to my patients.” – by Brian Ellis
Editor’s note: Dr. Woo is a paid consultant for Medtronic.
 |
Follow CardiologyToday.com on Twitter. |